Published on 8 Feb 2024 on Insider Monkey via Yahoo Finance
Is MEI Pharma (MEIP) Attractively Priced?
GreenWood Investors LLC, an investment management firm, released its annual 2023 investor letter. A copy of the same can be downloaded here. 2023 was excellent for the fund’s investors, thanks to the collaborative and constructive engagements, which added immense value to the performance. Despite that, the firm is still seeking more challenges to continue to drive forward. As for the 2023 returns, its separate accounts, open to any investor, delivered a remarkable return of 28.0%. In addition, you can check the top 5 holdings of the fund to know its best picks in 2023.
GreenWood Investors featured stocks such as MEI Pharma, Inc. (NASDAQ:MEIP) in the fourth quarter 2023 investor letter. Headquartered in San Diego, California, MEI Pharma, Inc. (NASDAQ:MEIP) is a clinical-stage pharmaceutical company. On February 7, 2024, MEI Pharma, Inc. (NASDAQ:MEIP) stock closed at $4.51 per share. One-month return of MEI Pharma, Inc. (NASDAQ:MEIP) was -24.46%, and its shares lost 29.31% of their value over the last 52 weeks. MEI Pharma, Inc. (NASDAQ:MEIP) has a market capitalization of $30.049 million.
GreenWood Investors stated the following regarding MEI Pharma, Inc. (NASDAQ:MEIP) in its fourth quarter 2023 investor letter: